Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

• Nail Psoriasis
• Plaque Psoriasis

• Active Comparator: 1
  etanercept 50 mg SC injection twice weekly for 12 weeks reducing to etanercept 50 mg once weekly to week 24
  Intervention: Drug: etanercept
• Active Comparator: 2
  etanercept 50 mg SC once weekly for the complete 24 week treatment period
  Intervention: Drug: etanercept

Inclusion Criteria:

• 18 years of age or older

• Active, stable plaque psoriasis defined by the following criteria:

  • Body surface area (BSA) ? 10 % at screening and baseline
  • Or, PASI >10 at screening and baseline
  • Or, PGA of Psoriasis status of moderate or worse (moderate, marked, or severe) at screening and baseline
  • Or, DLQI > 10 at baseline
• Active fingernail psoriasis defined as target fingernail NAPSI ? 2 and overall NAPSI > 14 - Target nail is defined as the nail with the highest nail score (matrix+bed scores) at baseline. Should more than one fingernail have the same score, the target fingernail will be chosen by the investigator.
• Failure of at least one systemic psoriasis therapy for nail psoriasis
• Eligible to receive biologic therapy for psoriasis in accordance to local guidelines

Exclusion Criteria:

• Evidence of Skin conditions other than psoriasis
• Psoralen plus ultraviolet radiation (PUVA), cyclosporine, alefacept, methotrexate, acitretin, or any other systemic anti-psoriasis therapy within 28 days of study drug initiation
• Prior exposure to any TNF-inhibitor. Prior exposure to efalizumab